ERYTECH PHARMA launches a subscription of BSPCE warrants reserved for its main executives Post author:admERY Post published:January 28, 2014 Post category:Newsroom ERYTECH launch a subscription of BSPCE reserved for its main executives. You Might Also Like ERYTECH Announces Collaboration with Queen’s University to Advance its Product Candidate for Rare Metabolic Disorders July 12, 2017 ERYTECH Granted U.S. FDA Fast Track Designation for eryaspase in Second-Line Pancreatic Cancer April 28, 2020 ERYTECH Provides Business Update and Reports Financial Results for the Third Quarter of 2019 November 7, 2019
ERYTECH Announces Collaboration with Queen’s University to Advance its Product Candidate for Rare Metabolic Disorders July 12, 2017
ERYTECH Granted U.S. FDA Fast Track Designation for eryaspase in Second-Line Pancreatic Cancer April 28, 2020
ERYTECH Provides Business Update and Reports Financial Results for the Third Quarter of 2019 November 7, 2019
